On 3/9/26- Cigna removed the following medications from the Pathwell Specialty Pharmacy drug list:
- Prolia® (denosumab)
Bildyos® (denosumab‑nxxp)
Conexxence® (denosumab‑bnht)
Enoby™ (denosumab‑qbde)
Jubbonti® (denosumab‑bbdz)
Stoboclo® (denosumab‑bmwo)
What does this mean for your patients?
- The removed medications no longer require a Pathwell Specialty Provider
- Standard Prior authorization process for medical necessity applies
- https://static.cigna.com/assets/chcp/medical/resourceLibrary/coveragePolicies/index.html- for any medical policies
Find this type of content useful? Follow my blog!
- Salvation Army members: new insurance cards
- UHC Community health: prior auth for some electrical stimulation services
- Rhode Island Medicaid: update telehealth PT services
- Aetna Better Health NJ: new bundled oncology condition specific prior auth
- Aetna Better Health of NJ: Out of network provider reimbursement update

Leave a comment